These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7218662)

  • 1. Plasma protein binding in uremia: extraction and characterization of an inhibitor.
    Depner TA; Gulyassy PF
    Kidney Int; 1980 Jul; 18(1):86-94. PubMed ID: 7218662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired plasma phenytoin binding in uremia. Effect of in vitro acidification and anion-exchange resin.
    Depner TA; Stanfel LA; Jarrard EA; Gulyassy PF
    Nephron; 1980; 25(5):231-7. PubMed ID: 7383235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of drug binding defects in uremia in vitro by anion exchange resin treatment.
    Lichtenwalner DM; Suh B; Lorber B; Rudnick MR; Craig WA
    Biochem Pharmacol; 1982 Nov; 31(21):3483-7. PubMed ID: 7150368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced in vitro binding of tryptophan by plasma in uremia.
    de Torrente A; Glazer GB; Gulyassy P
    Kidney Int; 1974 Oct; 6(4):222-9. PubMed ID: 4427418
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia.
    Depner TA
    Kidney Int; 1981 Oct; 20(4):511-8. PubMed ID: 6458729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of salicylate binding to normal plasma by extracts of uremic fluids.
    Roman S; Gulyassy PF; Depner TA
    Am J Kidney Dis; 1984 Sep; 4(2):153-61. PubMed ID: 6475946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin.
    Mingrone G; De Smet R; Greco AV; Bertuzzi A; Gandolfi A; Ringoir S; Vanholder R
    Clin Chim Acta; 1997 Apr; 260(1):27-34. PubMed ID: 9101098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment.
    Nikolaev V; Sarnatskaya V; von Appen K; Ivanov A; Rotellar E; Haspar M; Klinkmann H
    Artif Organs; 1996 Jan; 20(1):17-23. PubMed ID: 8645124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of inhibitors of ligand: albumin-binding from uremic body fluids and normal urine.
    Gulyassy PF; Bottini AT; Jarrard EA; Stanfel LA
    Kidney Int Suppl; 1983 Dec; 16():S238-42. PubMed ID: 6588258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia.
    Allison TB; Comstock TJ
    Ther Drug Monit; 1988; 10(4):376-81. PubMed ID: 3201522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.